Maximizing Safety in the Conduct of Alzheimer's Disease Fluid Biomarker Research in the Era of COVID-19
(2020) In Journal of Alzheimer's disease : JAD 76(1). p.27-31- Abstract
The coronavirus disease 2019 (COVID-19) pandemic led to an abrupt halt of many Alzheimer's disease (AD) research studies at sites spanning the world. This is especially true for studies requiring in-person contact, such as studies collecting biofluids. Since COVID-19 is likely to remain a threat for an extended period, the resumption of fluid biomarker studies requires the development and implementation of procedures that minimize the risk of in-person visits to participants, staff, and individuals handling the biofluid samples. Some issues to consider include structuring the visit workflow to minimize contacts and promote social distancing; screening and/or testing participants and staff for COVID-19; wearing masks and performing hand... (More)
The coronavirus disease 2019 (COVID-19) pandemic led to an abrupt halt of many Alzheimer's disease (AD) research studies at sites spanning the world. This is especially true for studies requiring in-person contact, such as studies collecting biofluids. Since COVID-19 is likely to remain a threat for an extended period, the resumption of fluid biomarker studies requires the development and implementation of procedures that minimize the risk of in-person visits to participants, staff, and individuals handling the biofluid samples. Some issues to consider include structuring the visit workflow to minimize contacts and promote social distancing; screening and/or testing participants and staff for COVID-19; wearing masks and performing hand hygiene; and precautions for handling, storing, and analyzing biofluids. AD fluid biomarker research remains a vitally important public health priority and resuming studies requires appropriate safety procedures to protect research participants and staff.
(Less)
- author
- organization
- publishing date
- 2020
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Alzheimer’s disease, biofluids, biomarkers, COVID-19, safety
- in
- Journal of Alzheimer's disease : JAD
- volume
- 76
- issue
- 1
- pages
- 5 pages
- publisher
- IOS Press
- external identifiers
-
- pmid:32568212
- scopus:85087529539
- ISSN
- 1387-2877
- DOI
- 10.3233/JAD-200684
- language
- English
- LU publication?
- yes
- id
- be1a3a93-d365-414b-8067-92fcd7e514c1
- date added to LUP
- 2020-07-20 11:38:48
- date last changed
- 2024-10-03 05:39:56
@article{be1a3a93-d365-414b-8067-92fcd7e514c1, abstract = {{<p>The coronavirus disease 2019 (COVID-19) pandemic led to an abrupt halt of many Alzheimer's disease (AD) research studies at sites spanning the world. This is especially true for studies requiring in-person contact, such as studies collecting biofluids. Since COVID-19 is likely to remain a threat for an extended period, the resumption of fluid biomarker studies requires the development and implementation of procedures that minimize the risk of in-person visits to participants, staff, and individuals handling the biofluid samples. Some issues to consider include structuring the visit workflow to minimize contacts and promote social distancing; screening and/or testing participants and staff for COVID-19; wearing masks and performing hand hygiene; and precautions for handling, storing, and analyzing biofluids. AD fluid biomarker research remains a vitally important public health priority and resuming studies requires appropriate safety procedures to protect research participants and staff.</p>}}, author = {{Schindler, Suzanne E. and Jicha, Gregory A. and Nelson, Peter T. and Keene, C. Dirk and Blennow, Kaj and Molinuevo, José Luis and Masters, Colin L. and Hansson, Oskar and Teunissen, Charlotte E. and Galasko, Douglas and Shaw, Leslie M. and Levey, Allan I. and Silverberg, Nina}}, issn = {{1387-2877}}, keywords = {{Alzheimer’s disease; biofluids; biomarkers; COVID-19; safety}}, language = {{eng}}, number = {{1}}, pages = {{27--31}}, publisher = {{IOS Press}}, series = {{Journal of Alzheimer's disease : JAD}}, title = {{Maximizing Safety in the Conduct of Alzheimer's Disease Fluid Biomarker Research in the Era of COVID-19}}, url = {{http://dx.doi.org/10.3233/JAD-200684}}, doi = {{10.3233/JAD-200684}}, volume = {{76}}, year = {{2020}}, }